FDA Approves Biogen’s Drug for Rare Form of ALS
A new drug has been developed to target a genetic cause of a neurological illness. The drug, called Qalsody, will be sold by the pharmaceutical company Biogen.
The subscription excludes access to digital content from New York Times Games, Cooking, Wirecutter, or The Athletic. After 1 year your payment method will be automatically charged the introductory rate for every 4 week period. You will be charged until you cancel. The cancellation takes place at the end your current billing cycle. Taxes could apply. Terms and conditions of the offer are subject to change.